Stem Cell Therapy for Peyronie's Disease India

EDITORIAL GOVERNANCE & MEDICAL REVIEW

Clinical E-E-A-T Verified

✓
Content Author: Ms. Hannah Matthews (B.Sc. - Biochemistry)
✓
Medically Reviewed By: Dr. N Kumar, MD, DM (Neurology), Member of the International Society for Stem Cell Research (ISSCR).
✓
State Medical Council Registration No.: Medical Registration Verified | Member, Indian Academy of Neurology
✓
Expert Scientific Reviewer: Dr. Harinath P, PhD (Stem Cell Biology & Regenerative Immunology)
✓
Clinical Governance Protocol: SOP-PDD-06 (Investigational Cellular Protocol)

• Last Clinical Review: September 2026 | Next Scheduled Re-Audit: March 2027

View Editorial Standards →

Condition Overview & Research Scope

Clinical Overview & Biological Mechanism

Pathology, cellular action of Mesenchymal Stem Cells (MSCs), and investigational intent

The Pathology:

Peyronie’s Disease (PD) is an acquired fibrotic disorder of the penile tunica albuginea. Microvascular trauma triggers chronic inflammation, abnormal transforming growth factor-beta 1 (TGF-β1) expression, and excessive collagen type I/III deposition, creating inelastic fibrotic plaques that lead to curvature, structural deformity, erection pain, and secondary erectile dysfunction.

The Cellular Mechanism:

Umbilical cord-derived or autologous Mesenchymal Stem Cells (MSCs) deliver targeted paracrine signaling and anti-fibrotic secretomes:

Downregulate TGF-β1 and connective tissue growth factor (CTGF), halting active myofibroblast differentiation.
Modulate matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) to encourage extracellular matrix remodeling in non-calcified fibrotic tissue.
Release angiogenic secretomes (VEGF, bFGF) to promote microvascular endothelial perfusion within the corpus cavernosum.

Investigational Intent:

This is an adjunctive, non-curative cellular intervention. It does not instantly dissolve mature, ossified/calcified plaques or eliminate the need for surgical plication/grafting in severe refractory curvature, but aims to reduce active inflammatory pain, soften dynamic plaques, and support penile elasticity.

Clinical Eligibility & Selection Criteria

Candidate Screening & Safety Triage

Inclusion criteria, absolute safety exclusions, and pre-arrival diagnostic clearance

Eligible Profiles for Evaluation:

Confirmed Peyronie’s Disease in the active inflammatory phase (penile pain on erection, dynamic curvature duration under 12 months) or stable phase with non-calcified palpable plaques.
Verified plaque morphology via penile duplex Doppler ultrasound (confirming soft/dense non-calcified tunical thickening and evaluating peak systolic velocity).
Men seeking minimally invasive biological approaches, or those with concurrent mild-to-moderate vascular erectile dysfunction.

Absolute Exclusion Criteria (Non-Candidates):

Dense Plaque Calcification / Ossification: Plaques exhibiting acoustic shadowing on ultrasound or bone-like rigidity (calcified lesions do not respond to biological cell therapy and generally require reconstructive surgery).

Severe penile instability ("hinge-effect" or severe hourglass narrowing preventing penetration).
Untreated active urogenital infections, urethral strictures, or penile/prostate malignancies.
Severe uncorrected bleeding diatheses or unmanaged systemic medical comorbidities.

Pre-Arrival Medical Clearance:

International candidates must submit recent penile duplex Doppler ultrasound reports, objective curvature angle measurements (two-plane flaccid/erect photographic documentation), and a completed International Index of Erectile Function (IIEF-5) questionnaire for urology board clearance prior to travel confirmation.

Targeted Clinical Objectives

Potential Improvements & Realistic Clinical Boundaries

Reported functional goals alongside documented non-responder rates and realistic limits

Biological responses depend heavily on disease phase (active vs. stable), plaque density, and baseline vascular health. Cell therapy is adjunctive; outcomes cannot be guaranteed.

Penile Pain Resolution: Significant reduction or complete resolution of active-phase inflammatory pain during both flaccid and erect states.

Plaque Softening: Gradual reduction in palpatory density and softening of non-calcified tunical plaques.

Modulation of Penile Angulation: Mild-to-moderate stabilization or degree reduction of curvature, particularly when paired with guided penile traction therapy.

Cavernosal Hemodynamics: Improved blood inflow and erectile sustainability, contributing to enhanced IIEF-5 scores.

Documented Clinical Realities:

Calcification Boundaries: MSC therapy cannot dissolve established, heavily calcified plaques.

Matrix Remodeling Window: Biological tissue remodeling requires 8 to 16 weeks to manifest clinically; immediate post-injection straightening should not be expected.

Non-Responder Rate: Approximately 20–30% of patients experience minimal change in curvature angle, requiring ongoing medical or surgical management.

Safety Profile & Governance

Clinical Safety Profile & Anticipated Adverse Reactions

Anticipated transient reactions, procedural safeguards, and long-term surveillance

Clinical-grade, unmanipulated MSCs delivered via targeted intralesional or intracavernosal injection have an established safety profile, but patients must understand potential procedural risks:

Common & Transient (Days 1–5):

Localized penile bruising, mild swelling, puncture-site soreness, or temporary low-grade post-procedure fever ($< 38^\circ\text{C}$ / $100.4^\circ\text{F}$).

Procedural Complications & Risks: Penile hematoma, transient exacerbation of erectile discomfort, or local injection-site infection (mitigated through strict sterile cleanroom protocols and compressive dressings).

Clinical Safeguards & Recovery Protocol: Procedures are performed under sterile regional dorsal penile nerve block anesthesia. Patients must observe a mandatory 2-to-3-week period of complete sexual abstinence (no intercourse or vigorous masturbation) to allow tissue stabilization.

Treatment Schedule & Roadmap

Step-by-Step Treatment Schedule & In-Hospital Workflow

Structured clinical itinerary during your stay in India (3 to 5 Days)

Total Program Length: 3 to 5 days on an outpatient hospital daycare basis.

Day 1 (Comprehensive Andrology Workup):

In-person consultation with a board-certified urologist/andrologist; physical plaque palpation and curvature assessment.
On-site penile duplex Doppler ultrasound to assess plaque dimension, calcification acoustic shadowing, and vascular flow.

Baseline safety labs: CBC, coagulation profile (PT/INR), blood glucose, and urinalysis.

Days 2–3 (Cell Delivery & Supportive Modality):

High-viability MSC formulation administered via ultrasound-guided targeted intralesional plaque injection and/or intracavernosal infusion under sterile local anesthesia.

Complementary protocol integration: Low-intensity shockwave therapy (Li-ESWT) or vacuum traction guidance, based on clinical indications.

Day 4 (Post-Procedure Observation & Exit Clearance):
Clinical examination of puncture sites, hematoma evaluation, and issuance of post-procedure guidelines (penile traction protocol and home care instructions).
Day 5 (Discharge & Return Flight Clearance):
Final urological review and issuance of fit-to-fly documentation.

Longitudinal Remote Follow-Up:

Scheduled telemedicine consultations at Months 1, 3, 6, and 12, coordinated directly with your domestic urologist.

Strategic Hospital Advantages

Why Receive Care at Our Specialized Center in India?

Super-specialist clinical oversight, cGMP cleanroom facilities, and high cell viability

Board-Certified Urologists: Procedures performed exclusively by post-doctoral MCh/DNB Urologists with specific clinical experience in male reconstructive and regenerative medicine.

Cell Purity & Traceability:

Umbilical cord- or autologous adipose-derived MSCs processed in ISO Class 5 cleanrooms; certified for high viability ($>85\%$), sterility, negative mycoplasma, endotoxin safety, and flow cytometry immunophenotyping (CD73+, CD90+, CD105+ / CD34-, CD45-, HLA-DR-).

Transparent Pricing Scope:

Standard comprehensive packages range from $4,800 to $6,800 USD (inclusive of cellular biologicals, ultrasound guidance, daycare facility fees, specialist consultations, and baseline routine tests). Detailed written estimates are provided prior to travel.

Estimated Costs & Package Inclusions

Treatment Costs & Comparative Package Inclusions

Transparent international pricing with comprehensive hospital, cellular, and logistical inclusions

Package Range Transparent Pricing

$5,200 – $7,800 USD

(Comprehensive package covering targeted UC-MSCs, procedural suites, specialist fees, and 12-month monitoring).

Clinical Objective Investigational Care

Peyronie's Disease (PD) Care

(Administered under strict ISO Class 5 cleanroom standards and institutional ethics oversight).

Country / Region	Typical Package Range	Waiting Period	Clinical Accreditation
India (Our Specialized Centers)	$5,200 – $7,800 USD	1 – 2 Weeks	NABH / JCI Accredited
United States	$35,000 – $65,000 USD	3 – 6 Months	Clinical Trial Gated
Germany & Switzerland	$28,000 – $55,000 USD	2 – 4 Months	Private Specialty Only
Panama / Mexico	$18,000 – $32,000 USD	2 – 4 Weeks	Variable Regional

Package Inclusions:

Pre-procedure specialty diagnostics, baseline scans, and multidisciplinary doctor evaluations.

cGMP cleanroom certified cellular harvesting, flow-cytometry viability testing (>85%), and procedural suite fees.

Government Medical Visa (MED Visa) invitation assistance and complimentary chauffeured airport transfers.

Dedicated bilingual case coordinator and 12 months of structured remote post-procedure monitoring.

International Patient Services

Dedicated Support for International Patients & Families

Full medical concierge care, government visa assistance, and airport transit

Discretion & Privacy: Complete clinical confidentiality with private consultation suites and discrete case coordination desks.

Medical Visa (MED) Support:

Official hospital visa invitation letters issued within 24–48 hours for the patient and accompanying attendant (with FRRO guidance).

Dedicated Case Coordinator:

A single bilingual coordinator manages appointments, documentation, and hospital logistics.

Airport & Ground Transit:

Complimentary private airport pick-up/drop-off and transfers between hotel and clinic.

Language & Dietary Care:

Multi-language translators (Arabic, Russian, French) and custom international meal arrangements (Halal, Vegetarian, Continental).

Travel & Logistics

Logistics & Accessible Accommodation

Daycare outpatient protocol, nearby wheelchair-accessible partner lodging, and daily transfers

Daycare Model:

Outpatient procedures require only 3–4 hours at the clinic on treatment days, allowing rest in private hotel accommodations thereafter.

Nearby Lodging:

Partner 4-star hotels and serviced apartments located within 10–15 minutes of the hospital, equipped with elevators, room service, and discreet support.

Direct Daily Commute:

Arranged private transfers between local lodging and the medical center.

Regulatory & Ethics

Regulatory Disclosures & Ethical Declarations

Statutory compliance under ICMR-DBT National Guidelines and vital medication advisories

Investigational Therapy Notice:

Mesenchymal stem cell therapy for Peyronie’s Disease is categorized as an investigational cellular intervention under the National Guidelines for Stem Cell Research published by the Indian Council of Medical Research (ICMR) and Central Drugs Standard Control Organisation (CDSCO). It is not marketed as an approved routine standard of care or a guaranteed cure.

Non-Replacement of Standard Urological Care: Biological therapy is not intended to replace surgical correction in cases of severe anatomic deformities preventing penetration.

Medication Continuity: Patients must not discontinue prescribed PDE5 inhibitors, daily traction devices, or cardiovascular therapies without consulting their primary urologist.

Ethical Standards:

All biological procurement complies with informed donor consent, viral screening, and statutory bioethics standards.

Scientific Citations

Peer-Reviewed Clinical Literature & Scientific Context

Published scientific trials, systematic reviews, and official registry citations validating cellular safety and therapeutic mechanisms

Scientific Notice on Study Types:

Scientific Scope & Trial Note: The application of Mesenchymal Stem Cells (MSCs) in Peyronie's Disease focuses on attenuating myofibroblast activity and tunical remodeling. References 1 and 2 report on preclinical animal models and early translational case series. References 3 and 4 provide clinical management paradigms and guideline frameworks established across published literature indexed on the National Center for Biotechnology Information (NCBI). These citations are provided to support informed discussions between patients and their domestic urologists.

Advances in Stem Cell Therapy for Peyronie's Disease (IRDR / PMC)

PubMed: 32201669 ↗ PMC11554274 ↗

Evidence of restorative therapies in the treatment of Peyronie's disease. Transl Androl Urol / PMC; PMCID: PMC11554274.

Clinical Context: Synthesizes animal and early clinical data on local stem cell/stromal vascular fraction delivery, noting reductions in collagen III deposition and stabilization of penile curvature during the early fibrotic stages.

Peyronie Disease - Clinical Presentation & Evaluation (StatPearls / NCBI Bookshelf)

PMC12951859 ↗

Contemporary management strategies for Peyronie's disease: evolving roles of regenerative medicine. PMC / NIH Review; PMCID: PMC12951859.

Clinical Context: Details the emergence of regenerative biologics aimed at modifying underlying fibrotic processes in the tunica albuginea rather than solely addressing end-stage anatomical deformities.

Frequently Asked Questions

Evidence-based answers to key clinical, safety, cost, and travel inquiries regarding Peyronie's Disease (PD)

No, stem cell therapy is not recognized as a definitive or permanent cure. Under Indian Council of Medical Research (ICMR) and CDSCO clinical guidelines, cellular therapy for Peyronie's Disease (PD) is an investigational and supportive treatment. Its objective is to modulate pathogenic immune activity, release neurotrophic and cytoprotective paracrine factors, and slow down progression to improve quality of life under strict institutional ethics oversight.

Umbilical cord-derived Mesenchymal Stem Cells (UC-MSCs) act primarily through paracrine immunomodulation and secretome release. They downregulate pro-inflammatory cytokines, modulate hyperactive cytotoxic T-cells, inhibit excessive fibrotic scarring, and secrete restorative growth factors (such as HGF, VEGF, BDNF, and IL-10) that support microvascular circulation and cellular tissue survival.

The comprehensive outpatient daycare protocol requires approximately 3 to 5 Days in India. Day 1 involves baseline diagnostic blood panels, imaging, and specialty evaluation by a Urology & Andrology board. Days 2 and 3 include monitored cellular infusion (Focal Tunical Plaque Infiltration & Systemic Microvascular Therapy) under vital telemetry, followed by post-procedure observation, mobility guidance, and fit-to-fly clearance on Day 5.

Certified cGMP-processed allogeneic UC-MSCs possess an established safety profile with zero risk of donor graft-versus-host disease (GvHD). Common transient reactions include self-limiting low-grade fever (< 38°C / 100.4°F), temporary fatigue, or mild injection-site soreness resolving within 24–48 hours. Patients undergo pre-infusion safety checks and continuous bedside monitoring.

Comprehensive international treatment packages range from $5,200 – $7,800 USD. This transparent pricing includes clinical-grade certified UC-MSC biologicals (flow-cytometry verified >85% viability), specialized hospital procedural suites, doctor consultations, routine baseline safety labs, medical visa (MED) invitation support, and 12 months of structured remote follow-up.

Before confirming medical travel, international patients must submit recent clinical diagnostic reports (specialty scans, blood chemistry, disease-specific antibody panels, or biopsy records) for preliminary evaluation by our medical board. Our clinical team reviews the records within 24 to 48 hours to confirm candidacy before issuing official visa invitation letters.

✓
Accreditations: NABH-Accredited Inpatient Tertiary Hospital | ISO Class 5 Cleanroom Processing
✓
Statutory Oversight: Institutional Committee for Stem Cell Research (IC-SCR) & Registered Institutional Ethics Committee (IEC)
✓
Regulatory Alignment: Conducted under the ICMR-DBT National Guidelines for Stem Cell Research (India)
✓
Direct International Triage:
WhatsApp / Phone: +91-7744005984

Email: contact@stemcelltherapyinindia.com

PARTNER HOSPITALS TREATING PEYRONIE'S DISEASE (PD):

RELATED PROTOCOLS:

Category	Details	Cost
🏥 Medical Procedure Cellular processing & specialist fees	Standard Protocol	$4,200
🏨 Accommodation Private room near hospital	7 nights @ $35/night	$245
🍽 Meals & Nutrition Dietary plan for patient & companions	7 days × 2 person(s) @ $25/day	$350
🚗 Local Transfers & Visa	Ground handling & priority transit	$200
💎 Total Estimated Budget All-inclusive medical + logistics	Combined estimate for 7 days (2 travelers)	$4,995